Your browser doesn't support javascript.
loading
Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers.
DiSilvestro, Jessica B; Haddad, Jessica; Robison, Katina; Beffa, Lindsey; Laprise, Jessica; Scalia-Wilbur, Jennifer; Raker, Christina; Clark, Melissa A; Lokich, Elizabeth; Hofstatter, Erin; Dalela, Disha; Brown, Amy; Bradford, Leslie; Toland, Maris; Stuckey, Ashley.
Afiliación
  • DiSilvestro JB; Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • Haddad J; The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • Robison K; Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • Beffa L; Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • Laprise J; Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • Scalia-Wilbur J; Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • Raker C; Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • Clark MA; The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • Lokich E; The School of Public Health, Brown University, Providence, Rhode Island, USA.
  • Hofstatter E; Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • Dalela D; Cancer Genetics and Prevention Program, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
  • Brown A; Cancer Genetics and Prevention Program, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
  • Bradford L; Department of Medical Oncology, Hartford Healthcare Cancer Institute, Hartford, Connecticut, USA.
  • Toland M; Division of Gynecologic Oncology, Maine Medical Partners, Scarborough, Maine, USA.
  • Stuckey A; Division of Gynecologic Oncology, Maine Medical Partners, Scarborough, Maine, USA.
J Womens Health (Larchmt) ; 33(5): 624-628, 2024 May.
Article en En | MEDLINE | ID: mdl-38488054
ABSTRACT

Objective:

To determine the utilization of risk-reducing strategies and screening protocols for ovarian cancer in female BRCA1/2 carriers.

Methods:

This study was a sub-analysis of female participants from a larger multicenter, cross-sectional survey of BRCA1/2 mutation carriers unaffected by cancer. The questionnaire was administered electronically via email at four institutions located in the northeast United States. Data were analyzed with Fisher's exact test.

Results:

The survey was completed by 104 female BRCA mutation carriers. BRCA subtypes included 54.3% BRCA2, 41.0% BRCA1, and 2.9% both. The age at which patients underwent genetic testing varied 21.2% were 18-24 years, 25.0% were 25-34 years, 29.8% were 35-44 years, and 24.0% were 45 years or older. Nearly, all respondents (97.1%) reported that a provider had discussed risk-reducing surgeries. Of the 79 females who underwent genetic testing before 45 years of age, 53.2% reported that a health care provider recommended taking combined oral contraceptive pills (COCs) to reduce their risk of ovarian cancer, and, of these women, 88.1% chose to use them. COCs were offered at higher rates among women who were younger at the age of genetic testing (18-24 86%, 25-34 62%, 35-44 23%; p < 0.0001). Approximately half (55.8%) of the respondents reported having been offered increased screening for possible early detection of ovarian cancer, of which 81.0% chose to undergo screening. The majority utilized a combination of transvaginal ultrasound and serum CA125 measurements. There were no differences observed in screening utilization based on BRCA mutation type.

Conclusion:

In our cohort of female BRCA mutation carriers, risk-reducing surgery was offered to almost all women, whereas only half were offered risk-reducing medication and/or increased screening. Further investigation is needed to identify barriers to the utilization of risk-reducing strategies among this high-risk population.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Neoplasias Ováricas / Pruebas Genéticas / Conducta de Reducción del Riesgo / Mutación Límite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Revista: J Womens Health (Larchmt) Asunto de la revista: GINECOLOGIA / SAUDE DA MULHER Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Neoplasias Ováricas / Pruebas Genéticas / Conducta de Reducción del Riesgo / Mutación Límite: Adolescent / Adult / Female / Humans / Middle aged Idioma: En Revista: J Womens Health (Larchmt) Asunto de la revista: GINECOLOGIA / SAUDE DA MULHER Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...